Correlation of serum CA 15-3 with histological types of breast cancer

Mahwish Nowshad; Fozia Rauf; Naveed Sharif; Ishfaq Ishfaq; Ambareen Gul; Naeemullah Naeemullah

doi:10.53730/ijhs.v7nS1.14464

Authors

Mahwish Nowshad
moonlight5578@gmail.com
IPDM Khyber Medical University, Peshawar
Fozia Rauf Peshawar Medical College
Naveed Sharif Khyber Medical University
Ishfaq Kuwait Teaching Hospital
Ambareen Gul Mercy Teaching Hospital
Naeemullah Women and Children Hospital Charsadda

Keywords:

Correlation, serum CA 15-3, histological types, breast cancer

Abstract

Background: The incidence of breast cancer and its fatal effects are constantly on a rise across the globe. Breast cancer is the most common cancer in Pakistan with approximately 1 in every 9 Pakistani women developing breast cancer at some stage of their life. There is a constant search for better screening methods which help in early detection and also reflect upon the prognosis of the tumor. CA 15-3 is a reliable serum marker that also helps in identifying patients who would benefit most from adjuvant therapy. Objective: To determine the correlation of serum CA 15-3 with histological types of breast cancer. Methodology: This prospective cross sectional study was conducted on 51 cases of female carcinoma breast from December 2015 to August 2016. The specimens were collected after mastectomy or lumpectomy and then transported to collection Shaukat Khanum Lab and city lab for chemical analysis and histopathological analysis. All the data was analyzed by using SPSS version 17. Results: In the current study, a total of 51 patients were included. Results of serum CA 15-3 level ranged from 3 to 743.2 U/ml (with mean of 40.62).

Downloads

Download data is not yet available.

References

World Health Organization. The Global Burden of Disease: 2004 Update Geneva: World Health Organization: 2008.

Babu GR, Samari G, Cohen SP. Breast cancer screening among females in Iran and recommendations for improved practice: a review. Asian Pac J Cancer Prev. 2011; 12: 1647-55.

Siegel R, Naishadham D, Jemal A. Cancer statistic. CA Cancer J Clin.2012; 62:10-29

Asnarulkhadi Abu S, Ahmadian M. Socio-demographic correlates of participation in mammography:a survey of women aged between 36-69 in Tehran. Iran. Asian Pacific J Cancer Prev.2012; 13:2717-20.

Seth T, Kotwal, Thakur RK, Ganguly KK. A study on community perception of common cancers ca, determinants of community behavior and program implentation in New Delhi.India .Asian Pac J Cancer Prev.2012; 13(6):1723-5.

Cancer Registry and Clinical Data Management (CRCDM) Shaukat Khanum Memorial Cancer Hospital and Research Center (SKMCH&RC) - (www.shaukatkhanum.org.pk). Report based on cancer cases registered at SKMCH&RC from Dec. 1994. Dec. 2012 and in 2012. Released June, 2013.

Bhurghuri Y. Karachi cancer registry data implications for the national cancer control program of Pakistan. Asian Pacific J Cancer Prev. 2004; 5:77–82.

Khan SM, Gillani J, Nasreen S, Zai S.Cancer in North West Pakistan and Afghan Refugees. JPMA, 1997; 47(122):122-124.

Tasneem S, Naseer F, Shahid S, Nasreen S, Khan MM, Javed N. A study of prognostic markers and stage of presentation of breast cancer in southern region of Khyber pakhtunkhwa,Pakistan. J.Med Sci. 2012 April; 20(2): 263-66.

Jardines L, Goyal S, Fisher P, Weitzel J, Royce M, Goldfarb SB. Breast Cancer overview: Risk Factors, Screening, Genetic Testing, and Prevention. Can Network. 2015 June.

Lester SC.The Breast. In: Kumar V, Abbas AK, Fausto N, Aster JC, editors. Robbin and Cotran Pathologic Basis of Disease. 8th ed.Philadalphia, PA 19103-2899: Saunders; 2010. P. 1144-7.

Daly MB, Axilbund JE, Buys S: Genetic/familial high risk assessment:Breast and ovarian. J Natl Compr Canc Netw.2010; 8:562-594.

Domcheck SM, Bradbury A, Garber JE, et al:Multiplex genetic testing for cancer susceptibility:Out on the high wire without a net? J Clin Oncol. 2007; 31:1267-1270

Robson ME, Storm CD, Weitzel J, et al:American Society of Clinical Oncology policy statement update:Genetic and genomic testing for cancer susceptibility . J Clin Oncol.2010; 28:893-901.

Breast Cancer - Moose and Doc. Breast Cancer information - by Moose and Doc [Internet]. 2015 [cited 9 June 2015]. Available from: http://breast-cancer.ca/.

Muhammad A, Nadira M, Adeel A, Sajid M, Khadim MT. Histological and Immuno-histochemical Study of Male Breast Carcinoma in Northern Pakistan. Journal of Pakistan Medical Association. 2009 Feb; 2:223.

Jemal A, Center MM, DeSantis C, Ward EM.Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev .2010; 19: 1893-907.

Fan NJ, Gao CF, Zhao G, Wang XL, Liu QY. Serum peptidome patterns of breast cancer based on magnetic bead separation and mass spectrometry analysis. Diagn ¬Pathol. 2012; 20: 45.

Kaustubh S Chaudhari , Prashant S Patil ,Sumeet S Pawar ,Nikhil N, Role of Pre-Operative Serum CA 15-3 Level in risk stratification of Breast Cancer Tambe Indian Journal of Basic & Applied Medical Research; September 2013: Issue-8, Vol.-2, P. 1117-112055.

Kufe,D.W. Mucins in cancer:Function, prognosis and therapy. Nature reviews cancer.2009; 9:874-885.

Keshaviah et al. CA 15-3 and alkaline phosphatase as predictors for breast cancer recurrenc:a combined analysis of seven international Breast Cancer Study Group trials. Annals of Oncology. 2007; 18:701.

Molina R, Auge JM, Farrus B, Zanon G, Pahisa J, Munoz M, Torne M, Filella X, Escudero JM, Fernandez P, Velasco M, Prospective evaluation of carcinoembryonic antigen carbohydreate antigen 15.3 in patients with primary locoregional breast cancer. Clin Chem. 2011; 56:1148-57.

Geng BENG, Liang MM, Ye XB, Zhao WY. Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. Mol Clin Oncol. 2015 Jan; 3(1):232–236.